Xenetic Biosciences, Inc. · NASDAQ:XBIO
Xenetic Biosciences — Investor Presentation (January 2021)
24 slides from Xenetic Biosciences's investor presentation, Jan 19, 2021
Slide 1: Expanding the Potential of CAR T Cell Therapy
Expanding the Potential of CAR T Cell Therapy NASDAQ: XBIO xeneticbio.com 2021 Investor Presentation JANUARY
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation contains forward - looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation other than statements of historical facts may constitute forward - l
Slide 3: Investment Highlights
Investment Highlights 3 Advancing XCART Ρ , a personalized CAR T platform targeting cancers with a patient - and tumor - specific approach Building on the proven success of CAR T therapy Following established roadmap for significant early - stage value creation Takeda: ongoing royalty stream through
Slide 4: Team with Proven Expertise
Team with Proven Expertise 4 Jeffrey F. Eisenberg Chief Executive Officer & Director Life Sciences executive with over 20 years of successful track record in value creation in both private and public companies; former CEO of Noven Pharmaceuticals, responsible for leading 2 product launches and Noven
Slide 5: Scientific Advisory Board with Extensive Cell Therapy Development Experience
Scientific Advisory Board with Extensive Cell Therapy Development Experience 5 Dr. Matthew Frigault Medical Oncologist in the Hematologic Malignancy Program at the Massachusetts General Hospital Cancer Center, as well as Assistant Director of the Cellular Immunotherapy Program; serves as Instructor
Slide 6: Personalized CAR T platform targeting cancers with a patient- and tumor-specific approach
Personalized CAR T platform targeting cancers with a patient - and tumor - specific approach 6 Platform
Slide 7: Lymphoma
Lymphoma 7 Group of blood cancers that develop from lymphocytes located in the lymph system Two Types of Lymphocytes B - Cells T - Cells Produce and secrete antibodies in the form of B - Cell receptors ( BCR) which selectively target a given antigen Helper T - Cells: modulate the function of B - Cel
Slide 8: B Cells and Tumor Growth
B - Cells and Tumor Growth 8 Tumor develops with the unique BCR clone B - Cell receptor (BCR) vs CD19 Current commercial therapies only target the common CD19 receptor that is present on all B - Cells CD19 CD19 Normal B - Cells Malignant B - Cell Proliferation (Retains Unique BCR) >1,000,000,000 Uni
Slide 9: Anti-CD19 CAR T Therapies Work…
Anti - CD19 CAR T Therapies Work… 9 1: https://my.clevelandclinic.org/health/treatments/17726 - car - t - cell - therapy/risks -- benefits; 2: https://www.fiercepharma.com/pharma/ash - gilead - touts - astounding - yescarta - survival - results - at - 3 - years Current CAR T therapies target both no
Slide 10: …But There Is Need For Improvement
…But There Is Need For Improvement 10 CAR T Relapse: lack of durable response T - Cell Exhaustion: progressive loss of CAR T effector function Toxicity Problems: Cytokine Release Syndrome (CRS) Neurotoxicity B - Cell Aplasia: elimination of all B - Cells Significant shortcomings with currently appro
Slide 11: CD19 Escape: Emergence of CD19- Tumor Cells
CD19 Escape: Emergence of CD19 - Tumor Cells Resulting from Anti - CD19 Treatments, including CAR T 11 Estimated percentage of patients who relapse due to CD19 escape 2 ∼ 10 - 50% Of patients have a lower count of CD19 - positive B - Cells due to prior therapies 2 10 - 15% Incidence of CD19 escape i
Slide 12: Anti-CD19 CAR T Targets the Tumors' Unique BCR
Anti - CD19 CAR T Targets the Tumors’ Unique BCR 12 Ability to address the CD19 escape phenomenon Malignant B - Cell Malignant B - Cell with CD19 Escape Unique BCR CD19 Unique BCR CD19
Slide 13: Only Targets Malignant B Cells
Only Targets Malignant B - Cells 13 Potential for increased efficacy, safety and tolerability over currently approved CAR T therapies Malignant B - Cell Targeted Unique BCR Presents Tumor - Specific Target Only Malignant B - Cells Eliminated Normal B - Cells are Spared CD19 CD19 Unique BCR Unique BC
Slide 14: Selectively Kill Raji Lines Expressing Target BCRs
Selectively Kill Raji B - Cell Lines Expressing Target BCRs 14 Raji B - cells (Raji - FL1, Raji - FL2 and Raji - FL3) expressing BCRs from the respective FL lymphomas were lysed by activated human CD8+ T cells bearing a corresponding cyclopeptide - CAR construct 1 Human CD8+ T cells were transduced
Slide 15: XCART Addresses Need in Current Lymphoma Treatment Paradigm
XCART Addresses Need in Current Lymphoma Treatment Paradigm 15 Follicular Lymphoma (FL) ~14,000/year US Incidence 1 Diffuse Large B - Cell Lymphoma (DLBCL) ~26,000/year US Incidence 1 1 st Line Therapy: ~11,000 Patients 2 nd Line Treatment: ~5,000 Patients XCART Opportunity: 3 rd Line Treatment ~3,0
Slide 16: Leveraging Academic Collaborations
Leveraging Academic Collaborations Expediting development pipeline with proven expertise and capabilities 16
Slide 17: Driving Development Through Academic Collaborations
Driving Development Through Academic Collaborations 17 Commencing clinical manufacturing process Initiating exploratory patient biopsy study in Eastern Europe Seeking U.S. FDA INTERACT meeting File U.S. IND Commence Phase 1 Trial in Eastern Europe Upcoming Potential Milestones Access to Manufacturin
Slide 18: Academic Collaborator
Academic Collaborator 18 Leading research institution with world renowned immunology expertise One of the original developers of the XCART platform Design and implementation of the preclinical development program Method development activities supporting process development for clinical manufacturing
Slide 19: Academic Collaborator: Pharmsynthez
Academic Collaborator 19 PHARMSYNTHEZ Optimize the overall XCART workflow Develop clinical manufacturing processes Access to clinical centers and B - Cell non - Hodgkin lymphoma (NHL) patients Conduct Phase 1 trial P1 Research organization coordinating activities with partnered academic institutions
Slide 20: PolyXen PSA Technology Platform Enables Next Generation Biologic Drugs
PolyXen ® PSA Technology Platform Enables Next Generation Biologic Drugs 20
Slide 21: PolyXen: Next Generation Half-Life Extension Platform
PolyXen : Next Generation Half - Life Extension Platform Technology 21 Polysialylation employs the biological polymer polysialic acid (PSA) to modulate the PK and PD profiles of protein drugs Generating Royalty Stream Platform for Partnerships Extensive IP protection Clinically demonstrated to exten
Slide 22: Financial Snapshot
Financial Snapshot NASDAQ: XBIO 22 Cash runway expected to fund Company through preclinical advancements towards IND filing Market Cap 1 Shares Outstanding Average Volume 1 ~8.75M ~$23.5M ~3.6M Cash Balance ~$7.1M as of September 30, 2020 ~$6M Does not include gross proceeds from Registered Direct O
Slide 23: Investment Summary
Investment Summary 23 Advancing XCART program through preclinical development into the clinic as quickly as possible Positioning to have a transformative impact in the CAR T space Truly differentiated CAR T technology Lead program targeting growing $8.8 billion non - Hodgkin lymphoma market 1 PolyXe
Slide 24: Expanding the Potential of CAR T Cell Therapy
Expanding the Potential of CAR T Cell Therapy NASDAQ: XBIO xeneticbio.com JTC Team, LLC. T: 833 - 475 - 8247 xbio@jtcir.com
Xenetic Biosciences — Investor Presentation (January 2021) on 6ix